Key receptors for T2DM treatment include the insulin receptor (IR), sodium-glucose cotransporter 1 (SGLT1), dipeptidyl peptidase-IV (DPP-IV), protein tyrosine phosphatase 1β (PTP1β), and aldose reductase (AR) (3). Here, SLC5A1 is linked to type 2 diabetes mellitus.